- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05004909
Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream
August 9, 2021 updated by: Dr.dr.Irma Bernadette, SpKK (K)
Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream Before and After 30% Trichloroacetic Acid Chemical Peeling on Aging Skin
This clinical study will compare the efficacy of using one fingertip unit and two fingertip units of 0.05% before and after 30% trichloroacetic acid chemical peel procedure for facial skin rejuvenation in 35-60 years old female patients with Glogau II-III skin classification.
Study Overview
Detailed Description
This study is an experimental study with a randomized controlled trial (RCT) design on patients who met the inclusion criteria.
Group A will receive pretreatment in the form of 0.05% tretinoin cream which is used as much as one fingertip unit every night, and group B will receive the same cream which should be used as much as two fingertip units.
This cream will be used for two weeks before the patients receive a chemical peeling therapy using 30% trichloroacetic acid.
The results of therapy will mainly be assessed based on the Dermoscopic Photoaging Scale (DPAS), as well as visual analog scale (VAS) for subjective symptoms and Clinician Erythema Assessment Scale (CEA) for erythema.
Study Type
Interventional
Enrollment (Anticipated)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jakarta Pusat
-
Jakarta, Jakarta Pusat, Indonesia, 10430
- Indonesia dr. Cipto Mangunkusumo Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female patients aged 35-60 years old
- Patients with Glogau II-III skin classification
- Patients are willing to participate in the study and sign an informed consent form
Exclusion Criteria:
- Patients with hypertrophic scars or keloid on the face
- Patients with open wound or infection on the face
- History of other topical treatment on the face within 1 month of enrollment
- Pregnant or breastfeeding mother
- Patients and/or their families are not willing to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1 Fingertip Unit 0.05% Tretinoin
Subjects were randomized to receive the instructions to use 1 fingertip unit of 0.05% tretinoin cream for 2 weeks before the first chemical peeling.
After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
|
Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
|
|
Experimental: 2 Fingertip Units 0.05% Tretinoin
Subjects were randomized to receive the instructions to use 2 fingertip units of 0.05% tretinoin cream for 2 weeks before the first chemical peeling.
After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.
|
Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of Photoaged Skin Condition
Time Frame: Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure
|
using dermoscopic photoaging scale (DPAS).
This DPAS assessment is based on yes or no rules on 11 criteria in four facial regions, namely left malar, right malar, forehead, and chin.
The criteria were yellowish discoloration, white line, lentigo, hypo- and hyper-pigmented macules, telangiectasia, yellow papules, actinic keratosis, senile comedones, deep wrinkle, superficial wrinkle, and criss-cross wrinkle.
Score range is 0-44 points.
|
Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure
|
|
Change of Subjective Pain Evaluation
Time Frame: Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure
|
using Visual Analog Scale (VAS).
Scale range is 0-10, 0 indicates no pain and 10 indicates severe pain
|
Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure
|
|
Change of Erythema Degree
Time Frame: Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure
|
using Clinician Erythema Assessment Scale (CEA).
Scale range is 0-4, 0 indicates no erythema and 4 indicates severe erythema
|
Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure
|
|
Change in Skin Thickness
Time Frame: Baseline(pre-chemical peeling procedure) and 4 weeks after chemical peeling procedure
|
Evaluation with USG of epidermal and dermal layer (in pixels)
|
Baseline(pre-chemical peeling procedure) and 4 weeks after chemical peeling procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2021
Primary Completion (Anticipated)
December 30, 2021
Study Completion (Anticipated)
January 31, 2022
Study Registration Dates
First Submitted
July 27, 2021
First Submitted That Met QC Criteria
August 9, 2021
First Posted (Actual)
August 13, 2021
Study Record Updates
Last Update Posted (Actual)
August 13, 2021
Last Update Submitted That Met QC Criteria
August 9, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TretandTCAPeeling
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Photoaging
-
Integrative Skin Science and ResearchSytheon Ltd.Not yet recruitingThe Effects of Zinc Di-(Dibutyryl Lisinate) on Skin Health and the Skin Microbiome in Photoaged SkinPhotoagingUnited States
-
Northwestern UniversityActive, not recruiting
-
University of ManchesterUnknownPhotoagingUnited Kingdom
-
Universitätsklinikum Hamburg-EppendorfRecruiting
-
Integrative Skin Science and ResearchNational Mango BoardNot yet recruiting
-
Bausch Health Americas, Inc.Completed
-
Galderma R&DCompletedPhotoagingUnited States
-
Derming SRLCompleted
-
Revision SkincareKGL, Inc.CompletedWrinkle | PhotoagingUnited States
-
University of California, DavisCompleted
Clinical Trials on 0.05% Tretinoin
-
Taro Pharmaceuticals USACompleted
-
Tishreen UniversityCompleted
-
Goldman, Butterwick, Fitzpatrick and GroffBausch Health Americas, Inc.Active, not recruiting
-
Coria Laboratories, Ltd.Completed
-
Coria Laboratories, Ltd.Completed
-
Coria Laboratories, Ltd.Completed
-
The Catholic University of KoreaCompletedVitiligoKorea, Republic of
-
Jinnah Postgraduate Medical CentreCompletedAcanthosis NigricansPakistan
-
Massachusetts General HospitalCompletedHyperpigmentationUnited States
-
Pontificia Universidad Catolica de ChileGalderma R&DCompleted